FZD2 and colon adenocarcinoma: Our findings demonstrate a positive correlation between FZD2 expression and TMB in cancers such as colorectal adenocarcinoma (COAD), supporting the hypothesis that FZD2 targeting could improve ICI efficacy, especially in tumors with high TMB.